Lumos Pharma Inc

Lumos Pharma — NewLink Genetics — BioCentury NewsMakers in the Biotech Industry 2013

38 slides from Lumos Pharma's conference presentation, Sep 26, 2013

  1. Slide 1: BioCentury NewsMakers in the Biotech Industry 2013

    Slide 1: BioCentury NewsMakers in the Biotech Industry 2013

    BioCentury NewsMakers in the Biotech Industry 2013 New York City

  2. Slide 2: Forward-Looking Disclaimer

    Slide 2: Forward-Looking Disclaimer

    Forward-Looking Disclaimer These slides accompany an oral presentation by NewLink Genetics Corporation, which contains forward-looking statements. The Company’s actual results may differ materially from those suggested here. Additional information concerning factors that could cause such a differenc

  3. Slide 3: NewLink Genetics Corporation: Oncology-Focused Biopharmaceutical Company

    Slide 3: NewLink Genetics Corporation: Oncology-Focused Biopharmaceutical Company

    NewLink Genetics Corporation Oncology-Focused Biopharmaceutical Company  Founded in 1999; IPO in 2011, Currently 100+ employees  Pipeline includes biologic and small molecule candidates  Completed enrollment for IMPRESS phase 3 trial  Strong IP position for technology platforms  Added to NASDAQ

  4. Slide 4: Targeting Immune Escape

    Slide 4: Targeting Immune Escape

    Blocking Immunosuppression “HyperAcute™” Vaccines* IDO Pathway Inhibitors Inducing Immune activation + V NewLink Genetics Targeting Immune Escape Developing two distinct, proprietary platforms that independently stimulate immune activation and disrupt tumor-mediated immunosuppression 4 *HyperAcute®

  5. Slide 5: NewLink Clinical Development Pipeline

    Slide 5: NewLink Clinical Development Pipeline

    NewLink Clinical Development Pipeline Targeting Immune Activation & Immunosuppression Product/ Tumor Type Phase 1 Phase 2 Phase 3 HyperAcute™ Platform Algenpantucel-L (pancreas) Tergenpumatucel-L (lung) HyperAcute Melanoma HyperAcute Prostate HyperAcute Renal Expected to enter clinical trials in 201

  6. Slide 6: HyperAcute Immunotherapy

    Slide 6: HyperAcute Immunotherapy

    HyperAcute™ Immunotherapy “Stimulating the immune system to recognize and attack cancer cells.” 6

  7. Slide 7: HyperAcute Platform

    Slide 7: HyperAcute Platform

    HyperAcute™ Platform Activation of Immune Response via Innate Immunity  Novel biologics designed to express alpha-gal carbohydrate which stimulates the immune system to recognize and attack cancer cells  Cellular immunotherapy that is tumor specific, but does not require tissue from the patient 

  8. Slide 8: Mechanism of Action

    Slide 8: Mechanism of Action

    Mechanism of Action HyperAcute Response  Tumor Specific Activity Dendritic Cells Macrophages Eosinophils NK Cells T-cells Complement Mediated Lysis Anti-α Gal Antibodies HyperAcute Immunotherapy Tumor Target Cell Tumor Specific Antibodies and T Cells CD8+ T Cells CD4+ T Cells Activated Dendritic Ce

  9. Slide 9: HyperAcute Immunotherapy Scale-up & Production

    Slide 9: HyperAcute Immunotherapy Scale-up & Production

    HyperAcute Immunotherapy Scale-up & Production • Disease specific yet NOT patient specific (Allogeneic) • Standardized, single site manufacturing • Established, scalable production methodology • Well characterized identity and potency Master Cell Bank (1000x) Production Lots Working Cell Banks (1000

  10. Slide 10: HyperAcute Immunotherapy Storage & Administration

    Slide 10: HyperAcute Immunotherapy Storage & Administration

    Shipping Storage Preparation Administration HyperAcute Immunotherapy • Vaccine is shipped on dry ice & stored at <-135°C. • Thawed to room temperature & drawn into a tuberculin syringe with 18g transfer needle. • Administered via 6 intradermal injections (25g needle) of 50 million cells each HyperAc

  11. Slide 11: Pancreatic Cancer Epidemiology & Pathophysiology

    Slide 11: Pancreatic Cancer Epidemiology & Pathophysiology

    Pancreatic Cancer Epidemiology & Pathophysiology 11  4th leading cause of cancer death in U.S.*  All stages, 5 year survival** < 5%  Stage IIB, resected, 5 year survival** <8%  Resection rate 20-25% U.S.*  Post resection standard of care  Chemotherapy +/- Radiotherapy  Gemcitabine +/- 5FU Con

  12. Slide 12: Algenpantucel-L Phase 2 Results: Resected Pancreatic Cancer

    Slide 12: Algenpantucel-L Phase 2 Results: Resected Pancreatic Cancer

    Algenpantucel-L Phase 2 Results: Resected Pancreatic Cancer  Eligibility & Treatment  Post-resection patients with no evidence of residual disease  SOC (gemcitabine+5FU+concurrent XRT) + algenpantucel-L  Algenpantucel-L schedule: Q2weeks X 6 months  High dose (300 million cells) & low dose (100

  13. Slide 13: HyperAcute Immunotherapy Safety

    Slide 13: HyperAcute Immunotherapy Safety

    HyperAcute Immunotherapy Safety Minimal Grade 3 & No Grade 4 Events  Most frequent AEs attributed to algenpantucel-L are grade 1/2 skin reactions at injection sites (51%)  Grade 3 events possibly attributable to vaccine: lymphopenia (6%), skin reaction/pain (3%) & leukopenia/neutropenia (3%)  No

  14. Slide 14: Prognostic Variables Impacting Survival

    Slide 14: Prognostic Variables Impacting Survival

    Prognostic Variables Impacting Survival Nodal Status & Tumor Size have Greatest Impact 14 Brennan Nomogram2 Validated Prognostic Variables N=555 Prognostic Variable Hazard Ratio P-Value Nodal Status 1.53 (1.18-1.97) 0.001 Tumor Size 1.21 (0.95-1.53) 0.12 Surgical Margin Status 1.05 (0.80-1.37) 0.74

  15. Slide 15: Pancreatic Cancer: Survival by Disease Stage

    Slide 15: Pancreatic Cancer: Survival by Disease Stage

    15 Stage 20,000 Patient Death Registry1 NLG 02052 1 Year (%) 2 Year (%) 3 year (%) Overall Survival Patient Distribution IA 71.3 50.2 40.7 24.1 mo 1% IB 67.3 45.4 35.3 20.6 mo 3% IIA 60.7 34.9 23.8 15.4 mo 15% IIB 52.7 23.8 14.4 12.7 mo 81% 2 Hardacre, J. et al, JCO, Vol 30, No 15_suppl (May 20 supp

  16. Slide 16: NLG0205: High Risk Patients w/ Poorer Prognosis

    Slide 16: NLG0205: High Risk Patients w/ Poorer Prognosis

    NLG0205: High Risk Patients w/ Poorer Prognosis Sponsor RTOG NewLink Study 97041 NLG 02052 Median Age 61 62 Gender (male) 53 % 53 % Whipple 85 % 86 % Lymph Node Positive 68 % 81 % Tumor ≥ 3 cm 61 % 66 % Poorly Differentiated 30 % 35 % CA 19-9 ≥180 9%** 18 % 16 2Hardacre, J. et al, JCO, Volume 30, No

  17. Slide 17: Resected Pancreatic Cancer Survival Rates vs. Controls

    Slide 17: Resected Pancreatic Cancer Survival Rates vs. Controls

    Resected Pancreatic Cancer Survival Rates NLG0205 vs. Predictive & Historical Controls 17 Trial 1 Year 2 year Overall Survival NLG-02051 86% 51% 24.1 mo RTOG 97042 69% 40%* 18.5 mo* Nomogram3 63% 32% 16.6 mo Hidalgo4 55% 26% 13.5 mo 1 Hardacre, J. et al, JCO, Volume 30, No 15_suppl (May 20 supplemen

  18. Slide 18: Algenpantucel-L Phase 2 Results: Long Term Follow Up

    Slide 18: Algenpantucel-L Phase 2 Results: Long Term Follow Up

    Algenpantucel-L Phase 2 Results: Long Term Follow Up at 3 Years *All patients ≥ 3 year follow up ** Developed by Memorial Sloan Kettering Cancer Center and validated by Massachusetts General Hospital patient cohort **Brennan, M. et al, (2004) Annals of Surgery, Volume 240(2): p. 293-8 **Ferrone, CR

  19. Slide 19: Algenpantucel-L Phase 2 Results: Overall Survival

    Slide 19: Algenpantucel-L Phase 2 Results: Overall Survival

    Algenpantucel-L Phase 2 Results: Overall Survival Hardacre, J. et al, JCO, Vol 30, No 15_suppl (May 20 supplement), ASCO 2012: Abstract 4049 NLG-0205 Nomogram Months Survi v a l Nomogram Median OS: 16.6 mo NLG0205 (All Patients) Observed Median OS: 24.1 mo 19 Relative survival benefit increases over

  20. Slide 20: NLG0205: Correlation of Survival & Antibody Elevation

    Slide 20: NLG0205: Correlation of Survival & Antibody Elevation

    Algenpantucel-L NLG0205: Correlation of Survival & Ab Elevation Antibody Elevation n Survival Rate (3 year) Median OS (months) p-value None 27 19% 17 One Parameter 26 42% 26 0.0476 Multiple Parameters 13 69% >36 (Not Reached) 0.0073 Assessed Parameters: anti-MSLN Ab, anti-CEA Ab and/or anti-αGAL Ab

  21. Slide 21: Algenpantucel-L Unexpected Clinical Observations

    Slide 21: Algenpantucel-L Unexpected Clinical Observations

    Algenpantucel-L Unexpected Clinical Observations  Recall skin reactions can occur 1-2 year after last vaccination  70% of patients showed eosinophilia; 30% lasted ≥ 1 year  CR to salvage chemotherapy (post algenpantucel-L therapy) in 3 patients with recurrent disease 0 2000 4000 6000 8000 10000 1

  22. Slide 22: Phase 3 Registration Trial - IMPRESS

    Slide 22: Phase 3 Registration Trial - IMPRESS

    Phase 3 Registration Trial - IMPRESS Surgically Resected Pancreatic Cancer  IMPRESS Trial* (n = 722)  Initiated, May 2010 under SPA with the FDA  FDA Fast Track and Orphan Drug  Open label, 2 arm, randomized study  Post surgical resection patients  SOC +/- algenpantucel-L (SOC = gemcitabine +/

  23. Slide 23: IMPRESS Patient Characteristics

    Slide 23: IMPRESS Patient Characteristics

    IMPRESS Patient Characteristics* Consistent with Previously Reported Large Studies Characteristics RTOG 97041 (n=221) IMPRESS (n≈700) Age (Median) 61 64 Gender (Male) 53 53 Disease Stage Ia N/R 4% Ib N/R 5% IIa N/R 21% IIb N/R 70% Nodal Status N0 32% 30% N1 68% 70% CA19-9 ≥180 9%** 9% 23 *Initial an

  24. Slide 24: Timing of IMPRESS Analysis

    Slide 24: Timing of IMPRESS Analysis

    Timing of IMPRESS Analysis Potential Factors Impacting Trigger Events  Patient characteristics  Age, gender, tumor size , stage, grade, Nodal status, CA19-9 etc…  New salvage treatment regimens  Gem+Abraxane, FOLFIRINOX, Tarceva  Enrollment rate (IMPRESS is in line with study projections)  Pos

  25. Slide 25: Second Phase 3 Trial - PILLAR

    Slide 25: Second Phase 3 Trial - PILLAR

    Second Phase 3 Trial - PILLAR Locally Advanced Pancreatic Cancer  Locally Advanced Trial* (n = 280)  Launched, October 2012 (FPI, Q113)  Open label, 2 arm, randomized study  FOLFIRINOX +/- algenpantucel-L  Algenpantucel-L: 300 million cells Q2 weeks up to 18 doses  Overall Survival is the prim

  26. Slide 26: Commercialization Strategy

    Slide 26: Commercialization Strategy

    Commercialization Strategy Algenpantucel-L for Patients with Pancreatic Cancer  NewLink plans to execute an independent US commercial launch  Leverage key pancreatic surgical centers as hubs  Provide strong product support across entire multidisciplinary team  Key launch components currently bei

  27. Slide 27: Lung Cancer Epidemiology & Pathophysiology

    Slide 27: Lung Cancer Epidemiology & Pathophysiology

    Lung Cancer Epidemiology & Pathophysiology 27  Leading cause of cancer death in U.S.*  All stages, 5 year survival 16%  Advanced disease, 5 year survival <5%  40% of patients present with metastatic disease  A significant unmet need exists for new treatment options for these patients U. S. Annu

  28. Slide 28: Tergenpumatucel-L Phase 2 Study – Previously Treated NSCLC

    Slide 28: Tergenpumatucel-L Phase 2 Study – Previously Treated NSCLC

    Tergenpumatucel-L Phase 2 Study – Previously Treated NSCLC  Single agent survival and safety results for 28 NSCLC patients  Median OS was 11.3 months with 46% of patients surviving one year  Favorable safety profile, no grade 4 drug related adverse events  Potential chemo-sensitization effect 

  29. Slide 29: Tergenpumatucel-L in NSCLC: Survival Correlates with IFN-g Response

    Slide 29: Tergenpumatucel-L in NSCLC: Survival Correlates with IFN-g Response

    Single Agent in Previously Treated NSCLC Tergenpumatucel-L in NSCLC Phase 2: Survival Correlates with IFN-g Response8 Morris, J. et al, JCO, Vol 31,_suppl (May 15 supplement), ASCO 2013: Abstract 8094 29

  30. Slide 30: Tergenpumatucel-L NLG-0301 Randomized Phase 2b/3 NSCLC

    Slide 30: Tergenpumatucel-L NLG-0301 Randomized Phase 2b/3 NSCLC

    30 Tergenpumatucel-L 300 M Cells Weekly or Biweekly Docetaxel 75 mg/m2 Q 3 weeks - 240 Patients - Previously Treated - Stage IIIb/IV NSCLC - PS 0-1 - >1,000 lymphocyte count Progression Standard Chemotherapy (gemicitabine, premetrexed or docetaxel) Standard Chemotherapy (gemicitabine or premetrexed)

  31. Slide 31: IDO Pathway Inhibitors

    Slide 31: IDO Pathway Inhibitors

    IDO Pathway Inhibitors Indoleamine 2,3-dioxygenase (IDO) “Disrupting mechanisms by which tumors evade a patient’s immune system.” NewLink Genetics IDO Pathway Inhibitors Indoximod NLG-919 31

  32. Slide 32: Cancer Immunosuppression: Three Key Checkpoint Targets

    Slide 32: Cancer Immunosuppression: Three Key Checkpoint Targets

    Cancer Immunosuppression Three Key Checkpoint Targets  CTLA-4  PD-1  IDO B7-1 or B7-2 CTLA-4 T cell PDL-1 or PDL-2 IDO APC (Dendritic Cell or Macrophage PD-1 Manipulation of IDO pathway related targets such as CTLA-4 and PD-1 offer potential breakthrough approaches to cancer therapy, targeting me

  33. Slide 33: IDO Supports Cancer Immunosuppression

    Slide 33: IDO Supports Cancer Immunosuppression

     Regulates immune response to cancer like CTLA-4 and PD-1  Inhibits effector T-cells, activates suppressive Tregs  Enables local tumor immune escape  Overexpressed  Within tumor cells or antigen presenting cells to directly suppress T- cells, must be targeted with a small molecule  NewLink act

  34. Slide 34: Indoximod Phase 1: Key Results Summary

    Slide 34: Indoximod Phase 1: Key Results Summary

    Indoximod Phase 1: Key Results Summary  Well tolerated, 200 mg QD to 2000 mg BID  Most common adverse events: fatigue, anorexia & nausea  Biologic effects observed in 3 patients previously sensitized to immunotherapy (low dose) & 2 non-sensitized patients (high dose)  Five patients with SD for ≥

  35. Slide 35: Indoximod + Docetaxel Combination Phase 1: Efficacy Results

    Slide 35: Indoximod + Docetaxel Combination Phase 1: Efficacy Results

    Indoximod + Docetaxel Combination Phase 1: Efficacy Results  18% (4/22) partial response rate (2 breast, 1 lung, 1 thymic)  41% (9/22) rate of stable disease -100% -80% -60% -40% -20% 0% 20% 40% 60% Fold Change in Tumor Volume NSCLC Esophageal Laryngeal Breast Thymic Rectal Pancreatic Ovarian 35

  36. Slide 36: Indoximod Clinical Development

    Slide 36: Indoximod Clinical Development

    36 Phase Design / Purpose/ Indication Status 1 Indoximod as single agent Dose escalation to determine MTD & PK All Solid malignancies Completed 1 Indoximod as single agent Dose escalation to determine MTD & PK All Solid malignancies Completed 1b/2 Indoximod + Docetaxel Dose escalation of both agents

  37. Slide 37: NLG-919 Preclinical Results & Next Steps

    Slide 37: NLG-919 Preclinical Results & Next Steps

    NLG-919 Preclinical Results & Next Steps  Potent Inhibitor (nM) of IDO in vitro and in cell based assays  Is orally bioavailable and has a favorable PK-Tox profile  Blocked IDO-induced T cell suppression (EC50 ~ 100 nM)  Enhanced antitumor activity in established tumors (B16F10)  Shows synergis

  38. Slide 38: Highlights & Future Direction

    Slide 38: Highlights & Future Direction

    NewLink Genetics Corporation Highlights & Future Direction  Multiple near term value-generating milestones expected  Accrual now complete for IMPRESS trial  Conduct first interim analysis for IMPRESS trial  Continue expansion of current clinical programs (PILLAR, lung, IDO, etc.)  Initiate new

Source: SEC EDGAR · 8-K filed Sep 26, 2013

More decks from Lumos Pharma Inc